Leerink Partnrs Weighs in on TENX FY2029 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for shares of Tenax Therapeutics in a research note issued to investors on Tuesday, February 4th. Leerink Partnrs analyst D. Risinger anticipates that the specialty pharmaceutical company will post earnings of $0.63 per share for the year. Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($0.88) per share.

Several other analysts also recently weighed in on TENX. Guggenheim started coverage on shares of Tenax Therapeutics in a research report on Monday, October 14th. They issued a “buy” rating and a $16.00 price objective on the stock. Leerink Partners began coverage on Tenax Therapeutics in a report on Thursday, October 24th. They set an “outperform” rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a sell rating, four have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Price Performance

Shares of TENX opened at $6.65 on Wednesday. The firm has a fifty day moving average of $6.08 and a 200-day moving average of $4.72. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $21.46.

Institutional Investors Weigh In On Tenax Therapeutics

Several institutional investors have recently bought and sold shares of TENX. Sphera Funds Management LTD. acquired a new position in Tenax Therapeutics during the 3rd quarter valued at about $101,000. Vestal Point Capital LP bought a new position in shares of Tenax Therapeutics in the third quarter valued at approximately $288,000. Finally, Stonepine Capital Management LLC acquired a new position in shares of Tenax Therapeutics during the third quarter valued at approximately $173,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.